Legal Claims due to Yasmin and Yaz cost Bayer $1.5 billion
In April 2012, consumers were alerted by the FDA that drospirenone, the active synthetic hormone ingredient used in Yasmin, Yaz, and Ocella, may be associated with increased risk of potentially fatal blood clots.
There are close to 10,000 pending lawsuits related to Yaz and Yasmin blood clot injuries with more than 1200 claims pending that have not yet been filed in court.
Bayer has been defending itself since 2009 against claims that allege the drugmaker knew about, or should have known about the dangerous side effects of Yaz, Yasmin, and Ocella.
Blood Clot Risk Warns by FDA
The claimants in the Yaz lawsuits have suffered injuries, some fatal, after taking Yaz, Yasmin, or Ocella. A study published in a British Medical Journal warns that the active ingredient, drospirenone, can increase the risk of deep vein thrombosis, blood clots, and pulmonary embolism by as much as 74 percent.
In reviewing the studies indicating risks, as well as studies that did not find any added risks, the FDA revised its safety labels for Yasmin, Yaz, and Ocells. The FDA added that some studies suggested as much of a three-fold increase in the risk of blood clots using birth control containing drospirenone, compared to other birth control that contain other synthetic hormones such as progesterone.
Bayer Settles Claims
Bayer, so far, has spent approximately $1 billion dollars, settling approximately 4,800 claims of blood clot related injuries by users of Yasmin, Yaz, and Ocella, though making no admission of liability. Bayer also states that 3,200 unsettled claims involve Yaz related blood clot injuries like deep vein thrombosis and pulmonary embolism.
In Bayer’s 2012 annual report, it stated that they will continue to evaluate blood clot settlements on a case by case basis.